Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats.
Chronic/relapsing experimental allergic encephalomyelitis (CREAE) serves as an animal model for relapsing/remitting multiple sclerosis. Treatment with the beta-adrenergic agonist isoproterenol or the beta 2-adrenergic agonist terbutaline significantly suppressed both the first acute attack and the number of relapses in CREAE Lewis rats. The number of relapses was decreased even when treatment with beta-adrenergic agonist was started after the onset of the first acute attack of CREAE. beta-adrenergic receptor number was increased significantly on splenocytes from CREAE rats as compared to healthy controls or CFA-injected rats. Terbutaline treatment of CREAE rats lowered the splenocyte receptor number to normal values.
Wiegmann
K
K
Department of Neurology, University of Chicago, IL 60637.
Muthyala
S
S
Kim
D H
DH
Arnason
B G
BG
Chelmicka-Schorr
E
E
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D002908:Chronic Disease; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000517:prevention & control*; D005260:Female; D007545:Isoproterenol / Q000627:therapeutic use; D016131:Lymphocyte Subsets; D008214:Lymphocytes / Q000737:chemistry; D051381:Rats; D011917:Rats, Inbred Lew; D011943:Receptors, Adrenergic, beta / Q000032:analysis; D013726:Terbutaline / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D011943:Receptors, Adrenergic, beta; D007545:Isoproterenol; D013726:Terbutaline